Drug intelligence / Profile preview

Onimex

Development stage
Unknown
Lead developer
Emcee Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Onimex is a range of oral cough and cold medications developed and marketed by Emcee Pharmaceuticals, an Indian pharmaceutical company. The product line includes several generic formulations designed to treat productive cough and associated respiratory symptoms. The standard formulation, including the sugar-free variant **Onimex SF**, contains the mucolytic agent **ambroxol** and the expectorant **guaifenesin**. Ambroxol works by thinning and loosening respiratory secretions, while guaifenesin increases the volume and reduces the viscosity of mucus, making it easier to expel. The **Onimex CZ** variant combines ambroxol with the antihistamine **cetirizine**, which addresses allergic symptoms such as runny nose, sneezing, and congestion by antagonizing H1 receptors. These products are administered as liquid syrups and are widely available as commercial generic formulations in India.

Brand names
OnimexOnimex SFOnimex CZ
Other names
ambroxol + guaifenesinambroxol + cetirizine
02

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Onimex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onimex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call